TransCode Therapeutics, Inc. — 2022 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2022. TransCode is a development-stage oncology biotechnology company focused on RNA therapeutics and diagnostics using its iron-oxide nanoparticle delivery platform. It reported no product revenue and had no product approved for sale. Its lead candidate, TTX-MC138, targets miR-10b in metastatic cancers.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $10.23 million | $2.75 million |
| General and administrative expense | $8.43 million | $3.40 million |
| Total operating expenses / operating loss | $18.67 million | $6.15 million |
| Grant income | $1.08 million | $0.28 million |
| Net loss | $17.56 million | $6.84 million |
| Basic and diluted loss per share | $1.35 | $0.81 |
| Net cash used in operating activities | $15.76 million | $5.27 million |
| Cash at year-end | $4.97 million | $20.83 million |
| Total assets | $7.59 million | $22.94 million |
| Total liabilities | $4.35 million | $2.53 million |
| Stockholders’ equity | $3.24 million | $20.40 million |
Profitability and liquidity. The company remained loss-making, with no revenue or meaningful gross margin to report. Cash and cash equivalents fell by about $15.86 million during 2022. The balance sheet showed no debt outstanding at year-end; accounts payable and accrued expenses were $4.35 million. Current assets of $7.38 million exceeded current liabilities of $4.35 million, but management said available resources would fund operations only into, not through, the second quarter of 2023, assuming receipt of expected grant funds. The auditor identified substantial doubt about the company’s ability to continue as a going concern.
Material changes versus 2021
- Net loss increased to $17.56 million from $6.84 million; R&D and G&A expenses rose substantially as the company expanded development and public-company activities.
- Operating cash use increased to $15.76 million from $5.27 million, while year-end cash declined from $20.83 million to $4.97 million.
- Grant income rose to $1.08 million from $0.28 million as more work was performed under the National Cancer Institute SBIR award.
- 2021 included derivative-liability and warrant-liability charges and interest expense associated with convertible notes; these items were absent in 2022 after the notes converted in connection with the 2021 IPO.
Outlook, developments, and principal risks
- Clinical development: FDA authorized the company to proceed with an exploratory Phase 0, first-in-human study of radiolabeled TTX-MC138 in December 2022. The planned study was intended primarily to assess delivery, biodistribution, and pharmacokinetics—not to establish therapeutic efficacy—and remained subject to institutional review board approval. The company planned to begin it in 2023 and continue IND-enabling work for a later Phase I/II study. The filing describes the other therapeutic programs as preclinical.
- Preclinical evidence: The company reported encouraging animal-model results for TTX-MC138 and TTX-siPDL1, but these findings are not evidence of safety or efficacy in human patients. A single feline case report described delivery and target engagement; the filing states that efficacy was not an objective of that investigation.
- Funding and dilution: In February 2023, the company raised approximately $1.3 million net by selling 2,846,300 shares at $0.527 per share, and expected about $0.9 million more under its SBIR award. Management said these funds would not support operations through the second quarter of 2023. Further financing is necessary and may dilute stockholders or require restrictive terms or the transfer of valuable rights.
- Commitments: A five-year MD Anderson collaboration includes a commitment to fund up to $10 million, with scheduled payments reaching $500,000 in the first year and larger payments in subsequent years. The filing says additional funds will be needed to meet later obligations.
- Reporting controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end because material weaknesses remained unremediated. Remediation was ongoing; timing and sufficiency were not assured.
- Listing risk: Nasdaq had notified the company of a minimum-bid-price deficiency. The filing contains inconsistent compliance-period dates: it identifies June 7, 2023 as the compliance date in one discussion, while other forward-looking language refers to a period ending July 7, 2023.
- Other risks: Key risks include early-stage clinical and regulatory uncertainty, reliance on third-party manufacturers and research providers, competition, dependence on licensed intellectual property, patient-enrollment and supply-chain delays, and the need to retain key personnel. The company also disclosed a 2021 phishing incident involving $526,435; the full amount was recovered by October 2021 and management considered the impact immaterial.
Important facts for investors to verify
- Confirm current cash, operating burn, grant receipts, and financing needs after the February 2023 offering; the reported runway was short and dependent on expected grant funding.
- Check whether the Phase 0 study received IRB approval, began enrollment, and produced results, and distinguish delivery or pharmacokinetic findings from evidence of clinical benefit.
- Review the precise Nasdaq bid-price compliance deadline and subsequent listing status, given the inconsistent dates in the filing.
- Track remediation of the material weaknesses and any subsequent changes to disclosure controls or financial reporting.
- Assess the timing and funding of MD Anderson collaboration payments and the potential dilution or other terms of future financing.
- Note a narrative inconsistency in the filing: the cash-flow discussion refers to 2022 net loss of approximately $17.925 million, while the audited financial statements report $17.565 million; verify against the audited statements and any later filings.